- Top of page
- Introduction to diabetes and global epidemics
- Type 2 diabetes as an auto-inflammatory disease
- IL-1 antagonism in type 2 diabetes: proof of concept study
- Long lasting IL-1β specific inhibitors
- Potential effects of IL-1β on insulin sensitivity
- Competing Interests
Metabolic diseases are associated with activation of the innate immune system in various tissues and characterized by elevated inflammatory factors and the presence of immune cells. Type 2 diabetes develops when islet beta cells are deficient in producing sufficient insulin to overcome peripheral insulin resistance. Intra-islet IL-1β activity diminishes beta cell function and survival and governs islet inflammation. Targeting the IL-1 system with the IL-1 receptor antagonist IL1Ra improved insulin secretion, glycaemia and reduced systemic inflammation in a proof of concept study with patients with type 2 diabetes. Currently, long lasting and specific IL-1β blocking antibodies are being evaluated in clinical trials and this may lead to a novel cytokine-based treatment for type 2 diabetes.